Chinese Japanese Germany Korea


Description References
Eptifibatide structure
Chemical Name:
Intrifiban;INTEGRELIN;Eptifibatide;Eptifibatide fandachem;Eptifibatide USP/EP/BP;Eptifibatide (free base);Eptifibatide acetate salt;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDE BRIDGE, MPA1-CYS6)
Molecular Formula:
Formula Weight:
MOL File:

Eptifibatide Properties

1.60±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,Store in freezer, under -20°C
CAS DataBase Reference

Eptifibatide price More Price(41)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 21578 Eptifibatide ≥95% 188627-80-7 5mg $37 2021-12-16 Buy
Cayman Chemical 21578 Eptifibatide ≥95% 188627-80-7 10mg $70 2021-12-16 Buy
Tocris 4725 Eptifibatide 188627-80-7 1 $85 2021-12-16 Buy
TRC E592000 Eptifibatide 188627-80-7 50mg $195 2021-12-16 Buy
TRC E592000 Eptifibatide 188627-80-7 100mg $360 2021-12-16 Buy

Eptifibatide Chemical Properties,Uses,Production


Eptifibatide is a kind of synthetic cyclic hexapeptide consisting of 6 amino acids and 1 mercaptopropionyl residue. It is capable of binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibiting the platelet aggregation, thus blocking the binding of the fibrinogen, von Willebrand factor and other adhesive ligands. It is indicated for the treatment of acute coronary syndrome (ACS) and Percutaneous coronary intervention (PCI). It is able to reduce the risk of acute cardiac ischemic events in patients with unstable angina or non-ST segment-elevation myocardial infection. It is often used in combination with aspirin or clopidogrel and heparin. It can be manufactured through solution-phase peptide synthesis, and can be purified by preparative reverse-phase liquid chromatography and lyophilization. 



Eptifibatide was first launched in the US (1998) as Integrilin for the iv treatment of acute coronary syndrome, in particular for patients at risk for abrupt vessel closure during or after coronary angioplasty. It is a synthetic cyclic heptapeptide based on rattlesnake venom disintegrin peptides and containing the RGD sequence (arginyl-glycyl-aspartyl) involved in the adhesive function of platelets. It can be prepared by classical solid-phase peptide synthesis or by fragment synthesis in solution. Eptifibatide is a reversible antagonist of the glycoprotein llb/llla complex, a specific platelet adhesion receptor that plays a central role in the cascade of thrombus formation by allowing mediators such as fibrinogen or von Willbrand factor to cross-link adjacent platelets and to give rise to aggregation. In diverse animal experimental models of arterial thrombosis, treatment with Eptifibatide resulted in an enhanced lysis of occlusive thrombus and a restoration of arterial blood flow. In clinical trials involving patients with acute coronary syndromes, Eptifibatide demonstrated a significant decrease in the incidence of death or nonfatal myocardial infarction at 30 days. In other trials in patients undergoing percutaneous coronary intervention (PCI), it showed a positive trend. Eptifibatide has the advantage of being short acting, its antiplatelet effect being rapidly reversible.


Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation. Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation. It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 μg/ml) in vitro and in vivo (IC50 = 52 μg/ml in porcine plasma). Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.


Cor Therapeutics (US)


An arginine-glycine-aspartate-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.


A Arginin-glycin-aspartat-mimetic, reversibly binds to platelets to reduce the risk of cardiac ischemic events.


ChEBI: A synthetic homodetic cyclic peptide comprising Nalpha-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulf de bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/I Ia receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures.

brand name


General Description

Eptifibatide (Integrilin) is a syntheticcyclic heptapeptide that acts as a GPIIb/IIIa receptor antagonist,thus causing inhibition of platelet aggregation. Itsstructure is based on the natural product barbourin, a peptideisolated from the venom of a pygmy rattlesnake (Sistrurusmilarud barbouri). As part of the structure, there is a sequenceRGD that can bind to the RGD receptor found onplatelets and block its ability to bind with fibrinogen. Thisagent is used in the treatment of unstable angina and for angioplasticcoronary interventions.

Mechanism of action

The drug is eliminated primarily via renal mechanisms as eptifibatide and deaminated eptifibatide. The clinical importance of eptifibatide and its benefits in comparison with other therapeutic agents used in the treatment of acute coronary syndromes and percutaneous coronary intervention have recently been reviewed by Curran and Keating

Clinical Use

Eptifibatide is a cyclic heptapeptide composed of six amino acids and one mercaptopropionyl residue. The cyclization is completed via a disulfide linkage between the cysteine and the mercaptopropionyl moieties. The lysine-glycine-aspartate component of eptifibatide is highly specific for the GPIIb/IIIa receptor, with low binding affinity, as indicated by the rapid dissociation constant. Because of this, eptifibatide is a reversible, parenterally administered antagonist of platelet aggregation.

Eptifibatide Preparation Products And Raw materials

Raw materials

Preparation Products

Eptifibatide Suppliers

Global( 194)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Cooperate Pharmaceutical Co.,Ltd
010-60279497 CHINA 1817 55
Hangzhou Go Top Peptide Biotech
0571-88211921 CHINA 2610 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 China 22607 55
Hangzhou FandaChem Co.,Ltd.
+86-571-56059825 China 9165 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 26781 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038 CHINA 3623 58
career henan chemical co
+86-0371-55982848 China 29953 58
Chengdu Biopurify Phytochemicals Ltd.
18482058008 18080483897 China 2712 58
08657186217390 CHINA 310 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28229 58

View Lastest Price from Eptifibatide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-11-09 Eptifibatide
US $0.00 / Kg/Bag 2Kg/Bag 99% min / FDA / DMF 20 tons Sinoway Industrial co., ltd.
2021-11-05 Eptifibatide
US $10.00 / Kg/Bag 1Kg/Bag 99% 20 Tons Hebei Zhanyao Biotechnology Co. Ltd
2021-11-04 Eptifibatide
US $10.00 / Kg/Bag 1Kg/Bag 99% 20 Tons Hebei Zhanyao Biotechnology Co. Ltd

188627-80-7(Eptifibatide)Related Search:

  • Eptifibatide acetate salt
  • Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2, >99%
  • Eptifibatide
  • N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
  • Intrifiban
  • N6-(AMinoiMinoMethyl)-N2-(3-Mercapto-1-oxopropyl)-L-lysylglycyl-L-.alpha.-aspartyl-L-tryptophyl-L-prolyl-L-cysteinaMide Cyclic (16)-Disulfide
  • 3-Mercaptopropionyl-HoMoarg-Gly-Asp-Trp-Pro-Cys-NH2
  • Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,{MPA}{HAR}GDWPC-NH2
  • L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-, cyclic (1→6)-disulfide
  • Eptifibatide fandachem
  • Eptifibatide USP/EP/BP
  • Eptifibatide (free base)
  • 188627-80-7
  • C35H49N11O9S2
  • Intermediates & Fine Chemicals
  • Peptides
  • Pharmaceuticals
Copyright 2017 © ChemicalBook. All rights reserved